Dong J-F, Whitelock J, Bernardo A, Ball C, Cruz M A
Thrombosis Research Section, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
J Thromb Haemost. 2004 Aug;2(8):1460-6. doi: 10.1111/j.1538-7836.2004.00830.x.
von Willebrand factor (VWF) freshly released from endothelial cells is normally cleaved by the ADAMTS-13 metalloprotease to prevent the direct release of these ultra-large (UL) and hyper-reactive multimers into plasma. The balance of ULVWF proteolysis may be regulated by the amount of ULVWF released and the processing capacity of ADAMTS-13. The former associates with the size of ULVWF storage pool, sensitivity of vascular endothelial cells to stimulation, and the type of agonists, whereas the latter associates with the activity of ADAMTS-13. These parameters may vary significantly among individuals. We have determined the variations of ADAMTS-13 activity in 68 normal individuals by a flow-based assay and a static assay using ULVWF strings and recombinant VWF A2 domain as substrates, respectively. We found that the levels of ADAMTS-13 activity required to cleave the platelet-decorated ULVWF strings under flow is significantly higher than that of static assays. Normal plasma diluted to 25% significantly reduced its ability to cleave ULVWF strings under flow, whereas 2% plasma retained 48% enzyme activity in static assay. ADAMTS-13 activity varied from 33 to 100% among individuals and the variations were greater at shorter incubations of plasma with the substrate. Furthermore, the production of ULVWF from endothelial cells also varied among individuals. These results suggest that the commonly used static assays may underestimate the ADAMTS-13 activity required to cleave newly released ULVWF. They also demonstrated that the proteolysis of ULVWF may vary significantly among individuals, potentially contributing to the individual's vulnerability to thrombosis so that measurement of ADAMTS-13 may serve as a marker for TTP and other thrombotic diseases.
从内皮细胞新释放的血管性血友病因子(VWF)通常会被ADAMTS-13金属蛋白酶切割,以防止这些超大(UL)且高反应性的多聚体直接释放到血浆中。ULVWF蛋白水解的平衡可能受ULVWF释放量和ADAMTS-13加工能力的调节。前者与ULVWF储存池的大小、血管内皮细胞对刺激的敏感性以及激动剂的类型有关,而后者与ADAMTS-13的活性有关。这些参数在个体之间可能有显著差异。我们分别使用基于流动的检测方法和以ULVWF链及重组VWF A2结构域为底物的静态检测方法,测定了68名正常个体中ADAMTS-13的活性变化。我们发现,在流动条件下切割血小板包被的ULVWF链所需的ADAMTS-13活性水平显著高于静态检测。正常血浆稀释至25%会显著降低其在流动条件下切割ULVWF链的能力,而2%的血浆在静态检测中保留了其48%的酶活性。个体之间ADAMTS-13活性从33%到100%不等,且血浆与底物孵育时间越短,差异越大。此外,内皮细胞产生ULVWF的情况在个体之间也有所不同。这些结果表明,常用的静态检测方法可能低估了切割新释放的ULVWF所需的ADAMTS-13活性水平。它们还表明,ULVWF的蛋白水解在个体之间可能有显著差异,这可能导致个体对血栓形成的易感性,因此ADAMTS-13的检测可作为血栓性血小板减少性紫癜(TTP)和其他血栓性疾病的标志物。